About vtv therapeutics inc - VTVT
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.
VTVT At a Glance
vTv Therapeutics, Inc.
3980 Premier Drive
High Point, North Carolina 27265
| Phone | 1-336-841-0300 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -26,974,000.00 | |
| Sector | Health Technology | Employees | 26 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
VTVT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.444 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -7.561 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
VTVT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,037,461.538 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
VTVT Liquidity
| Current Ratio | 13.536 |
| Quick Ratio | 13.536 |
| Cash Ratio | 13.391 |
VTVT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -42.093 |
| Return on Equity | -70.395 |
| Return on Total Capital | -41.861 |
| Return on Invested Capital | -70.395 |
VTVT Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |